PFS in patients undergoing endocrine therapy plus CDK4/6i was inversely correlated with Ki-67 expression, suggesting that tumor proliferation has a great impact on cell cycle inhibitors combined with endocrine therapy [32]. This evidence concerns the gene MKI67 and neoplasm.